1. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. (17th October 2017) Authors: Kalunian, Kenneth C; Urowitz, Murray B; Isenberg, David; Merrill, Joan T; Petri, Michelle; Furie, Richard A; Morgan-Cox, Mary-Ann; Taha, Rebecca; Watts, Steven; Silk, Maria; Linnik, Matthew D Journal: Rheumatology Issue: Volume 57:Number 1(2018) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Issue 9 (24th May 2022) Authors: Dörner, Thomas; Tanaka, Yoshiya; Dow, Ernst R; Koch, Alisa E; Silk, Maria; Ross Terres, Jorge A; Sims, Jonathan T; Sun, Zhe; de la Torre, Inmaculada; Petri, Michelle Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 9(2022) Page Start: 1267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION. (June 2019) Authors: Dörner, Thomas; Tanaka, Yoshiya; Petri, Michelle A; Smolen, Josef S.; Dow, Ernst; Higgs, Richard E; Rocha, Guilherme; Benschop, Robert; Silk, Maria; Bono, Stephanie de; Hoffman, Robert Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗